Bajaj Healthcare Reports Q4 FY26 Financial Results: 12.6% Revenue Growth, 35% Profit Rise
Mumbai, May 08, 2026: Bajaj Healthcare Limited, a prominent manufacturer of APIs, Intermediates, and Formulations, has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported key financial highlights for Q4 FY26 and the full fiscal year (FY26).According to the company's statement, the results showed robust growth in overall profitability, though the revenue from operations saw a minor contraction year over year for the quarter.
Key Financial Performance Highlights
The financial results for the quarter and year ended March 31, 2026, are detailed in the tables below:| Particulars (Rs. Mn) | Q4 FY26 | Q4 FY25 | Y-o-Y % Change | FY26 | FY25 | Y-o-Y % Change |
|---|---|---|---|---|---|---|
| Revenue from Operations | 1530.6 | 1,544.7 | (0.9%) | 6,110.3 | 5,426.0 | 12.6% |
| EBITDA | 256.3 | 253.3 | 1.2% | 1,119.5 | 1,018.3 | 9.9% |
| EBITDA Margin (%) | 16.7% | 16.4% | - | 18.3% | 18.8% | - |
| PAT from Cont. Operations\* | 138.3 | 115.9 | 19.3% | 545.6 | 429.3 | 27.1% |
| PAT Margin (Cont. Operations)\* | 9.0% | 7.5% | - | 8.8% | 7.9% | - |
| Profit for the period\* | 104.0 | 111.8 | (7.0%) | 490.1 | 395.0 | 24.1% |
| Profit for the period (%) | 6.8% | 7.2% | - | 7.9% | 7.3% | - |
The company also provided a revenue breakdown across key segments:
| Particulars (Rs. Mn) | Q4 FY26 | Q4 FY25 | Y-o-Y % Change | FY26 | FY25 | Y-o-Y % Change |
|---|---|---|---|---|---|---|
| API (Domestic) | 868.5 | 891.4 | (2.6%) | 3195.7 | 3267.1 | (2.2%) |
| API (Exports) | 385.4 | 407.5 | (5.4%) | 1881.4 | 1241.4 | 51.6% |
| Formulations | 276.7 | 245.8 | 12.6% | 1033.2 | 917.5 | 12.6% |
Operational and Strategic Updates
The company noted significant operational milestones alongside the financial performance.Product Development and Regulatory Achievements:
- Cenobamate, a novel anti-epileptic molecule, is proceeding through Phase III clinical trials as planned, with a planned launch in Q2 FY27. This strengthens the company's focus in the CNS space.
- Bajaj Healthcare has successfully completed the bioequivalence study for Suvorexant Tablets and is in the near term stages of filing the application with the DCGI.
- During Q4, the company filed 41 DMFs, bringing its cumulative total to 110. These filings contribute to strengthening the company’s global regulatory presence.
Business Expansion and Capitalization:
* In the current quarter, the company converted 2,079,409 warrants into equity shares, injecting additional capital amounting to INR 527 million to support growth initiatives and bolster the balance sheet.
Management Commentary:
Mr. Anil Jain, Managing Director, stated that the quarter faced a challenging operating environment, citing continued price erosion in domestic APIs and the early impacts of geopolitical disruptions in West Asia, leading to elevated raw material prices.
He highlighted that despite the stable year over year revenue, the Profit After Tax from continuing operations before exceptional items registered healthy growth of 19% year over year.
The MD further noted that FY26 revenue growth of 12.6% was propelled by a 51.6% year over year increase in API exports, driven by traction across regulated markets including the EU, UK, and LATAM. The formulations business also contributed robustly with 12.6% year over year growth.
The company also reported a reversal of income related to transferring technical know-how to manufacture a product for a party in the Middle East region. This reversal was executed after the customer was unable to meet financial commitments due to delays in regulatory approvals and ongoing regional instability in the Middle East.
Looking forward, Bajaj Healthcare remains focused on achieving export-led growth by strengthening its core API business and expanding its formulations business with an emphasis on higher-value products. The company is accelerating efforts in peptides, oncology, and CNS, supported by investments in manufacturing, capacity expansion, and R&D-led innovation.
BAJAJHCARE Stock Price Movement
On Friday, Bajaj Healthcare Limited shares slipped by 0.37% to settle at ₹336.55. The stock saw a notable trading volume of 416,278 shares during the session, trading within a range anchored by a low of ₹326.95.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: